The case for & against
Bull & Bear analysis
Bearish
Cassava Sciences, Inc. (NASDAQ: SAVA) is a clinical-stage biotechnology company focused on developing therapies for Alzheimer's disease and related disorders. Currently, Cassava is working on simufilam, its lead product, which is under investigation for its potential to modify the progression of Alzheimer's disease. The company's strategic transition includes a rebranding to Filana Therapeutics as it aims to leverage existing data to address central nervous system (CNS) disorders, particularly related to tuberous sclerosis complex (TSC)-related epilepsy, while also managing the future landscape of Alzheimer’s treatment.
Bull says
- ↑Ended Q3 with $149M cash, runway into 2026 despite $80–90M H2 burn.
- ↑Top-line Phase 3 results expected by year-end, potential catalyst for approval.
- ↑US Alzheimer’s market ~7M diagnosed; simufilam aims to outperform cholinesterase inhibitors.
- ↑Plasma biomarkers show high correlation with brain amyloid-β, supporting drug’s mechanism.
- ↑Solid cash reserves and positive trial outlook factor into growth narrative.
- ↑Rebranding to Filana Therapeutics widens focus toward CNS disorders beyond Alzheimer’s.
Bear says
- ↓Q3 net loss widened to $27.9M from $25.7M YOY; Q3 G&A rose to $12.9M.
- ↓Reserved $25M for legal challenges amid SEC scrutiny, boosting operating risk.
- ↓Must meet both ADAS-Cog12 and ADL endpoints for FDA success, elevating trial risk.
- ↓Average cash burn ~$18.5M/quarter YTD, high operational costs strain runway.
- ↓Competition from Eli Lilly and Biogen monoclonal antibodies intensifies market pressure.
- ↓Negative factor analysis flags high burn and regulatory hurdles as core risks.
Earnings Call · Q3 2024 · Mgmt. Guidance
Updated 05-09-2026neutral
Transcript signals
Bull points
- We expect to announce the top-line results of the trial before the end of this year.
- This is an exciting time for us. We remain optimistic that we will see promising data that could ultimately lead to a best-in-class treatment for Alzheimer's
- I am really proud to be associated with this team. And I'm truly grateful to these courageous doctors who have given simufilam the opportunity to demonstrate its potential by participating in our trials when it would have been so much easier to have just said no.
Bear points
- net cash used in operations during the nine months ended September 30 was $55.7 million, or roughly $18.5 million each quarter. Net cash used in operations for the second half of 2024 is expected to be between $80 million and $90 million. This is consistent with our previous guidance.
- Our net loss was $27.9 million, or $0.58 per share, in Q3 compared to a net loss of $25.7 million, or $0.61 per share, for the same period in 2023.
- General and administrative expense for Q3 were $12.9 million compared to $4.3 million for the same quarter last year. The significant increase was due primarily to higher legal-related expenses.
Read full transcript analysis ›